More, and less

UPSC Prelims + Mains Study Note

1. At a Glance

• Union Budget 2026-27 allocated ₹1,06,530.42 crore to the Ministry of Health and Family Welfare — a ~10% rise over Revised Estimates of FY 2025-26. [1]
• Despite the absolute increase, health spending remains ~1.9% of total government expenditure and only ~0.26% of GDP — well below the NHP 2017 target of 2.5% of GDP. [1][8]
• The budget is "more" on targeted schemes (biopharma, R&D, mental health) and "less" on systemic public health commitment as a share of national income.
• UPSC relevance: GS-II (health policy, government schemes); GS-III (pharma sector, R&D); GS-I (demography — ageing population).

2. Why in the News

• February 1, 2026: Finance Minister Nirmala Sitharaman presented Union Budget 2026-27; health sector triggered debate because:
• The Biopharma SHAKTI scheme (₹10,000 crore flagship) dominated health headlines. [2][3]
• Experts flagged that the 0.26% of GDP health allocation fell far short of pre-budget expectations that Budget 2026 would be a "milestone" for health spending. [8]
• India's demographic shift toward an ageing population raised urgency around geriatric care provisions. [8]

3. Background & Evolution

• National Health Policy 2017: Set a target of raising public health expenditure to 2.5% of GDP by 2025 — a target consistently missed. [5]
• FY 2014 → FY 2019: Government's share of Total Health Expenditure rose from 28.6% to 40.6%, signalling gradual improvement. [5]
• FY 2024: Government health expenditure reached approximately 1.84% of GDP (Union Health Minister J.P. Nadda, 2024), moving "steadily" toward 2.5%. [6]
• Previous budgets: Health budget rose incrementally each year but chronic under-investment in primary healthcare persisted.
• Post-COVID impetus: Pandemic highlighted gaps in healthcare infrastructure; successive budgets post-2021 attempted course correction through Ayushman Bharat, PM-ABHIM, and now Biopharma SHAKTI.

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• ₹10,000 crore Biopharma SHAKTI aims to reduce import dependence on biologics/biosimilars, strengthen India's position as a global pharma manufacturing hub. [3]
• Biologics and biosimilars market is high-value; domestic manufacturing could improve current account balance and generate high-skill employment.
• However, at 0.26% of GDP, overall health investment remains insufficient for a middle-income country targeting universal health coverage. [8]

Social

• Training 1.5 lakh geriatric care workers addresses a structural gap: India is transitioning to an ageing population (demographic shift). [8][7]
• Training 1 lakh allied health professionals tackles severe para-medical workforce shortage in Tier 2/3 cities and rural areas. [7]
• NIMHANS North India campus expands mental healthcare access — historically concentrated in south India — addressing regional equity. [8]

Scientific / Technological

• Creation of a pan-India network of 1,000 accredited clinical trial sites addresses India's long-standing weakness: low clinical trial density relative to global standards. [8]
• 3 new NIPERs + modernisation of 7 existing NIPERs will strengthen pharmaceutical R&D pipeline. [2]
• Biopharma SHAKTI specifically targets biologics (large-molecule drugs) and biosimilars — the fastest-growing segment of global pharma. [3]

Geopolitical / Strategic

• India's "China+1" opportunity in global pharma supply chains reinforced by Biopharma SHAKTI — positions India to capture market share in biologics manufacturing. [3]
• Increased AIDS/STD Control Programme allocation (₹3,477 crore, +30.64%) aligns with global UNAIDS 95-95-95 targets. [7]

Ethical / Governance

• Gap between rhetoric and allocation: NHP 2017 promised 2.5% of GDP by 2025; Budget 2026 delivers only 0.26% — governance accountability question. [8]
• Concentration of high-value schemes (Biopharma SHAKTI, clinical trials) in advanced-care tiers may deepen primary vs tertiary healthcare divide.
• Budget prioritises production-linked health innovation over preventive/primary care strengthening — an ethical allocation debate.

6. Recent Developments (Last 12-18 Months)

• February 1, 2026: Union Budget 2026-27 presented; MoHFW allocation at ₹1,06,530.42 crore. [1]
• February 2026: Biopharma SHAKTI scheme announced — ₹10,000 crore over 5 years for biologics/biosimilars manufacturing. [2][3]
• February 2026: Three new NIPERs announced; seven existing NIPERs to be modernised. [2]
• February 2026: Second NIMHANS campus to be established in North India; two upgraded national mental health institutes announced. [8]
• February 2026: 1,000 accredited clinical trial sites network proposed — addressed as a long-neglected R&D gap. [8]
• 2024 (preceding year): Health Minister Nadda stated health expenditure reached 1.84% of GDP in FY24 — still below NHP 2017 target. [6]
• FY 2024 data (PIB): Government's share in Total Health Expenditure rose to ~40.6% by FY19 (latest National Health Accounts data available). [5]

7. Prelims Hooks

1. Biopharma SHAKTI stands for: Strategy for Healthcare Advancement through Knowledge, Technology and Innovation. [3]
2. Budget 2026-27 allocates ₹10,000 crore to the Biopharma SHAKTI scheme over 5 years. [3]
3. Total MoHFW allocation in BE 2026-27: ₹1,06,530.42 crore — approximately 10% higher than RE 2025-26. [1]
4. Health allocation in Budget 2026 is approximately 0.26% of GDP and 1.9% of total government expenditure. [8]
5. NHP 2017 set a target of 2.5% of GDP for public health spending — not yet achieved as of 2026.
6. 3 new NIPERs to be established + 7 existing NIPERs to be modernised under Budget 2026. [2]
7. A second NIMHANS campus is to be set up in North India (existing NIMHANS is in Bengaluru). [8]
8. 1,000 accredited clinical trial sites to form a pan-India clinical trial infrastructure. [8]
9. Target: Train 1 lakh allied health professionals over the next 5 years. [7]
10. Target: Train 1.5 lakh geriatric care workers over the next 5 years. [7][8]
11. National AIDS & STD Control Programme allocated ₹3,477 crore in BE 2026-27 — a 30.64% increase over RE 2025-26. [7]
12. HR for Health & Medical Education allocation: ₹1,725 crore — rise of ₹95 crore (+5.83%) over RE 2025-26. [7]
13. Government's share of Total Health Expenditure rose from 28.6% (FY14) to 40.6% (FY19). [5]

8. Mains Relevance

GS Papers:

• GS-II: Government policies and interventions for development in various sectors; health sector; welfare schemes.
• GS-III: Indian economy — industrial policy; pharmaceutical sector; R&D and innovation.
• GS-I (tangential): Population and demographic changes — ageing India.

Syllabus Headings:

• GS-II: "Issues relating to development and management of Social Sector/Services relating to Health."
• GS-III: "Infrastructure — Health."

Plausible Mains Questions:

1. "Despite successive budgets increasing health allocations in absolute terms, India's public health expenditure as a share of GDP remains critically low. Analyse the structural reasons and suggest corrective measures." (GS-II)
2. "The Biopharma SHAKTI scheme signals a shift in India's health policy from service delivery to manufacturing competitiveness. Critically evaluate the priorities embedded in Union Budget 2026-27's health component." (GS-II/GS-III)
3. "India's demographic transition toward an ageing population demands a reorientation of health budgeting. Examine how Budget 2026-27 addresses — and falls short of — this imperative." (GS-I/GS-II)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Confusing 0.26% of GDP with 1.9% of total expenditure: Both figures are correct but measure different denominators. The 2.5% NHP target refers to % of GDP, not % of government expenditure — aspirants often mix these up.
2. NIMHANS location: Existing NIMHANS is in Bengaluru (Karnataka); the Budget 2026 announcement is for a new campus in North India — not a relocation.
3. NIPER count: Budget 2026 announces 3 new NIPERs + modernisation of 7 existing ones. Pre-budget there were 9 NIPERs across India. Do not conflate new establishments with upgrades.
4. Biopharma SHAKTI implementing ministry: It involves Dept. of Pharmaceuticals (Ministry of Chemicals & Fertilizers), not solely MoHFW — common confusion in multi-ministry schemes.
5. Allied Health vs Geriatric Care targets: 1 lakh = allied health professionals (clinical/para-medical); 1.5 lakh = geriatric/elderly care workers — these are two distinct training targets, often swapped in recall.